metastasis

Researchers from the "Differentiation and Cancer" group at i3S, in collaboration with “Cancer Metastasis” and “Cell Division & Genomic Stability” groups and Carmen Jerónimo from IPO-Porto, elucidated the role of YTHDF3, a key m6A RNA “reader” protein, as a driver of gastric cancer (GC) progression and paclitaxel sensitivity. This new study, entitled "The RNA‑binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN," was recently published in the journal "Gastric Cancer”.

i3S, Porto, Portugal

26 -27 October, 2023

See more informations here: https://aspicaseicameeting.aspic.pt/

i3S, Porto, Portugal

26 -27 October, 2023

See more informations here: https://aspicaseicameeting.aspic.pt/

Virtual event, Worldwide

6 - 7 December 2022

See more informations here: https://www.eacr.org/conference/metastasisdormancy2022virtual?utm_source=eacrnews&utm_medium=email&utm_campaign=vIPM22&utm_content=

Virtual event, Worldwide

6 - 7 December 2022

See more informations here: https://www.eacr.org/conference/metastasisdormancy2022virtual?utm_source=eacrnews&utm_medium=email&utm_campaign=vIPM22&utm_content=

On-line event

25-26 January, 2022

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

On-line event

25-26 January, 2022

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

Over 70% of breast cancers (BC) are estrogen receptor-positive (ER+). The Notch ligand Delta-like 1 (DLL1) is a key player in ER+ BCs development and aggressiveness and its overexpression are associated with poor prognosis. In this study, Portuguese researchers developed a novel anti-DLL1 antibody that inhibited tumor growth and liver metastases in a xenograft mouse model. The data suggests that anti-DLL1 immunotherapy can be a promising strategy for ER+ BC treatment.

Authors and Affiliations:

Mais de 70% dos cancros da mama são positivos para o recetor de estrogénio (ER+ BC). A expressão elevada da proteína DLL1 nestes tumores está associada a maior agressividade e por conseguinte a pior prognóstico. Neste estudo, investigadores portugueses desenvolveram um anticorpo capaz de impedir a formação de metástases hepáticas em modelos animais xenotransplantados. Este estudo sugere a inibição da proteína DLL1 como uma nova abordagem no tratamento de cancros da mama positivos para o recetor de estrogénio.

Autores e afiliações:

Even after apparently successful treatment of primary tumor, some undetectable tumor cells can persist and cause cancer to eventually come back. These cells spread beyond the primary tumor to other organs of the body, where they lay dormant until awakening into deadly metastases.